- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00062621
Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure
Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In very limited human testing, a combined kidney and bone marrow transplant appears to be safe and effective in treating multiple myeloma and associated kidney failure. This study will evaluate this approach in 10 patients with kidney failure due to or in association with stage II or greater multiple myeloma. Treatment prior to transplant will include cyclophosphamide, ATGAM (a lymphocyte-specific immunosuppressant), local radiation to the thymus, and cyclosporine (an immunosuppressive drug).
An infusion of donor bone marrow and a kidney graft from a closely matched, related donor will be transplanted simultaneously. An additional infusion of donor white blood cells may be administered between day 45 and 74 after transplant in an effort to eliminate any remaining cancer cells. Patients will remain on cyclosporine for a defined period of time. The cyclosporine doses will be slowly decreased and stopped if graft rejection and graft-versus-host disease do not occur.
Each participant will be involved in the study for 3 years; this includes the intervention phase (time from initial screening at approximately 7 days before transplant through 100 days after the transplant) and continued follow-up visits for at least 2 years following the transplant.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114-2696
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- End-stage renal disease (ESRD) due to or in association with stage II or greater multiple myeloma
- Participants in whom the development of ESRD is not due to the underlying myeloma will be included if they have evidence of active myeloma despite past treatment with standard therapies (e.g., prednisone, melphalan, high-dose radiation therapy with autologous stem cell transplantation)
- On dialysis or have a creatinine clearance greater than 20 ml/min
- HLA-matched or one of six HLA antigen-mismatched related donor
Exclusion Criteria:
- Compromised pulmonary, cardiac, or liver function
- Active infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Remission status of multiple myeloma
Time Frame: Throughout study
|
Throughout study
|
Renal allograft acceptance and ability to discontinue immunosuppressive therapy
Time Frame: Throughout study
|
Throughout study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Graft vs. host disease (GVHD)
Time Frame: Throughout study
|
Throughout study
|
Opportunistic infections
Time Frame: Throughouto study
|
Throughouto study
|
T-cell recovery and immune reconstitution
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Thomas Spitzer, MD, Massachussetts General Hospital
- Principal Investigator: A. Benedict Cosimi, MD, Massachussetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Kidney Diseases
- Urologic Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Renal Insufficiency, Chronic
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Kidney Failure, Chronic
- Renal Insufficiency
Other Study ID Numbers
- DAIT ITN008ST
- NKDO1
- DAIT NKDO1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Combined bone marrow and kidney transplant
-
Rabin Medical CenterRecruitingRenal TransplantationIsrael
-
Massachusetts General HospitalRecruitingBone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)Autoimmune Diseases | Multiple Myeloma | Hodgkin Disease | AL Amyloidosis | Myelofibrosis | Chronic Kidney Disease | Sickle Cell Anemia | Thalassemia | Aplastic Anemia | Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Non-Hodgkin... and other conditionsUnited States
-
St. Jude Children's Research HospitalCompletedOsteogenesis ImperfectaUnited States
-
Fred Hutchinson Cancer CenterUniversity of California, Los Angeles; Oregon Health and Science University; Ohio... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedSevere Aplastic AnemiaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Institutes of Health (NIH); National Institute on Aging (NIA)Active, not recruitingLymphoma | Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Non-Hodgkins Lymphoma | Blood CancerUnited States
-
University of NebraskaCompleted
-
University of Milano BicoccaIRCCS San RaffaeleCompletedLeukemia | BCR-ABL Positive | Myelogenous | ChronicItaly
-
Catherine BollardNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsRecruitingHIV Associated LymphomaUnited States
-
Hospital Universitario La FeUnknownOvarian ReserveSpain